Moberg Pharma announces that the company has decided to issue a five-year senior unsecured bond loan in the amount of SEK 300 million with maturity on January 29th, 2021.
The bond loan will give a floating rate coupon of Stibor 3m + 6.00% and have a total framework amount of SEK 600 million. Moberg Pharma intends to apply for listing of the bond loan on Nasdaq Stockholm within 30 days.
To enable future growth, Moberg Pharma intends to make significant investments during 2016, focusing on strengthening brand platforms for the company’s strategic brands in the U.S., increased international distribution, acquiring additional brands and initiating Phase III studies for MOB-015.
Carnegie Investment Bank and Swedbank have acted as financial advisors and Gernandt & Danielsson has acted as legal advisor in the transaction.
”We are pleased with the large interest among Swedish and Nordic investors for the bond loan, despite challenging market conditions. The access to the corporate bond market and non-dilutive financing strengthens our financial position further and is an important step in the financing of the company’s growth and acquisition strategy”, says Peter Wolpert, CEO Moberg Pharma.
Source: Moberg Pharma
